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2 Abstract
Chlamydia pneumoniae (Cpn) is a widely distributed human respiratory
pathogen, that has also been implicated in COPD and atherosclerosis. There
is strong evidence, that Cpn utilizes a Type 3 secretion system (TTSS) to ex-
port effectors out of its secluded, intracellular niche. A protein that has been
shown to be associated with the TTSS is chlamydial outer protein N (CopN).
Previous reports have shown the immunogenicity of CopN. Here, immuno-
genic epitopes of CopN were identified in BALB/c and C57BL/6 mice based
on protein immunizations and IFN-γ ELISpots with a peptide library. Using
these newly identified epitopes, it was possible to demonstrate the mucosal
efficacy of Intercell’s adjuvant IC31 R©. IFN-γ release of lung T cells from
animals immunized intranasally with CopN and IC31 R© could be detected,
as well as epitope-specific CD8+ T cells in BALB/c mice using MHC class
I pentamers. The relevance of CopN during a natural Cpn infection could
also be demonstrated using a cultured ELISpot approach. Potential T cell
factors, which might be differentially regulated during adjuvantation with
IC31 R© were suggested by means of an initial microarray experiment using
RNA from lung T cells.
The data shown here demonstrate efficient mucosal adjuvanticity of IC31 R©
when applied intrasally to mice, suggesting a potential use in the human sys-
tem.
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3 Zusammenfassung
Chlamydia pneumoniae (Cpn) ist ein weit verbreitetes humanes Pathogen
des Respirationstrakts, das auch mit COPD und Arteriosklerose in Zusam-
menhang gebracht wurde. Es wird vermutet, dass Cpn ein Type 3 secretion
system (TTSS) verwendet, um Effektormoleküle zu exportieren. Chlamydi-
al outer protein N (CopN) ist an das TTSS assoziiert. Frühere Publikatio-
nen berichteten über die Immunogenität von CopN. In dieser Arbeit wurden
immunogene Epitope von CopN in BALB/c und C57BL/6 Mäusen identifi-
ziert. Dies erfolgte mittels Immunisierung mit CopN und anschließenden IFN-
γ ELISpots mit einer Peptidlibrary. Anhand dieser neu identifizierten Epito-
pe konnte die Effizienz von IC31 R©, einem von Intercell entwickelten Adjuvans,
in intranasal immunisierten Tieren gezeigt werden. IFN-γ Ausschüttung von
T Zellen der Lunge aus Tieren, die mit CopN und IC31 R© intranasal immu-
nisert wurden, konnte gemessen werden. Weiters wurden Epitop-spezifische
CD8+ T Zellen in BALB/c Mäusen anhand von MHC I Pentameren detek-
tiert. Die Bedeutung von CopN während einer natürlichen Cpn Infektion
konnte in einem cultured ELISpot gezeigt werden. RNA aus T Zellen der
Lunge wurde für ein Microarray Trial-Experiment verwendet, um mögliche
T Zellfaktoren, die im Zuge einer Immunreaktion nach Gabe von IC31 R© un-
terschiedlich reguliert werden zu identifizieren.
Die hier beschriebenen Daten zeigen eine erfolgreiche Adjuvantizität von
IC31 R©, wenn es Mäusen intranasal dargeboten wird, was eine Applikation
im humanen System versprechend erscheinen lässt.
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4 Introduction
4.1 Chlamydia pneumoniae
Chlamydia pneumoniae (Cpn) is an obligate intracellular, Gram-negative eu-
bacterium that is widely distributed. It is a small pathogen with a genome
size of circa 1.2 Mbp [29]. Cpn is a causative agent of community-acquired
pneumonia, bronchitis, sinusitis and other respiratory diseases [31,41]. More-
over, Cpn has been implicated in asthma, chronic obstructive pulmonary
disease (COPD) [20] and atherosclerosis [9]. Throughout this thesis, the ex-
pression “Chlamydia pneumoniae” is used, despite recent suggestions of using
“Chlamydophila pneumoniae” instead, which is not yet universally accepted.
Chlamydiae have no detectable amounts of peptidoglycan, but contain a
dense array of disulfide cross-linked proteins in the outer membrane confer-
ring structural integrity [41]. Despite their small genome, Chlamydiae have
an intriguing biphasic life cycle, composed of a metabolically inert, infectious
form termed elementary body (EB) and a metabolically active, replicating
form termed reticulate body (RB). The EB of Cpn is typically pear-shaped
(unlike the round EBs of C. trachomitis), with a size < 0.5 µm [9,31].
During the first few hours of infection, EBs differentiate into RBs capable
of vegetative growth [14]. Throughout their developmental cycle, Chlamy-
diae are located within an intracellular, parasitophorous vacuole, also referred
to as inclusion. The inclusion remains separated from endolysosomal path-
ways [25] and intercepts Golgi-derived vesicles to acquire sphingolipids and
cholesterol [52]. After 18-20 hours after infection, a subset of RBs differenti-
ates into EBs, which can cause another infectious cycle.
Chlamydia trachomatis can exit the infected host cell in two ways: cellular
lysis and a packaged release mechanism referred to as extrusion [25]. Lysis
implicates a sequential degradation of the inclusion membrane, followed by
rupture of the host cell plasma membrane. In contrast, extrusion preserves
the life of the host cell, and only a portion of the inclusion is released, leaving
the host cell and the remaining inclusion intact.
In addition to the basic life cycle, Cpn is also able to endure suboptimal
replicative conditions in a persistent form. Known inducers of persistence are
deprivation of Fe and L-Trp [53]. The extrusion mechanism has also been
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suggested to play a role in persistence [25].
Chlamydiae modulate cellular functions in a variety of ways. The
pro-apoptotic effectors BAD and atypical PKCδ are inhibited. Chlamy-
dial protease-like activity factor (CPAF) degrades BH-3 only domain pro-
apoptotic proteins. Furthermore, CPAF degrades RFX-5 and USF-1 which
are involved in MHC gene expression. Finally, Chlamydiae severely impact
the cell cycle [24,52,54].
Several antibiotic agents were reported to be efficient against Cpn [31].
However, intensive long-term treatment is recommended in order to avoid
re-infection with persistent bacteria.
Resistance against Cpn requires an intact T cell compartment [53]. In
humans and mice, both CD4+ and CD8+ T cells were detected at the site of
infection. In the mouse model, experimentally induced absence of the latter
results in increased bacterial burdens as well as an increase in disease severity,
indicating a major importance of CD8+ T cells in the combat against this
pathogen [51,53]. This comes as no surprise, given the obligate intracellular
nature of Chlamydiae. Particularly, CD8+ T cells specific for known antigens
of Cpn belong to the Tc1 subset, secreting IFN-γ, TNF-α and MIP-1α [53].
As mentioned before, Cpn might be a risk factor in atherosclerosis. Evi-
dence comes from a multitude of seroepidemiological studies, which demon-
strate, that there is a significant association between antibodies specific for
Cpn and atherosclerosis. Furthermore, Cpn has been detected in foam cells
in atherosclerotic lesions, but only rarely in arterial tissues that are histolog-
ically normal [9].
4.2 Chlamydia outer protein N (CopN)
In 1997, four putative type III secretion system (TTSS) genes were identified
in Chlamydia psittaci [23]. Scc1, copN, cds1 and cds2 were suggested to
be potential candidates of TTSS components based on their homology to
Yersinia genes. After the genomes of Ctr and Cpn were sequenced in 1998
and 1999, respectively, it was found that these genes were conserved, further
indicating a functional relevance of the TTSS [14,29,45].
The first experimental evidence for the expression of Ctr CopN came from
Fields et al. in 2000 [14]. According to this study, CopN is present in EBs,
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RBs and whole culture extracts harvested 20 hours after infection. Moreover,
it was shown that CopN, which is homologous to YopN, could be secreted
by the Yersinia TTSS. CopN is believed to act as a peripherally asociated
“plug” of the injectisome, preventing unwanted passage.
CopN has been shown to interact with LcrH-2, which might function as
a chaperone [44]. A major finding further strengthening the assumption that
Chlamydiae possess a functional TTSS was the demonstration of ATPase
activity of CdsN [48]. The same group demonstrated the interaction of CopN
with CdsN, even at high salt concentrations.
Interestingly, heterologous expression of Cpn CopN in yeast and mam-
malian cells induced cell cycle arrest at the G2/M phase, presumably due to
alteration in the microtubule cytoskeleton [24]. Moreover, functional knock-
out of CopN activity by means of inhibitors abrogated Cpn growth in infected
cells, indicating an essential role of this protein.
Bearing these facts in mind, CopN is an attractive candidate for a future
vaccine against Cpn and potentially other members of the family. Intranasal
immunization of BALB/c mice with heat-aggregated CopN protein adju-
vanted in E. coli heat-labile toxin resulted in antigen-specific production of
antibodies and IFN-γ, lymphocyte proliferation and protection against Cpn
challenge [50].
4.3 Adjuvants
IC31 R© is a dual component adjuvant, composed of the antimicrobial, cationic
peptide KLKL5KLK (KLK) and an oligodeoxynucleotide composed of deoxy-
inosine/deoxy-cytosine repeats (5’-ICICICICICICICICICICICICIC-3’).
IC31 R© is able to induce local depot formation and to elicit a specific type
1 and type 2 as well as a cytotoxic T cell response in mice [42]. According
to extensive toxicological studies in rats, IC31 R© did not cause any toxic
effects [42].
In addition to the adjuvant properties described in mice, IC31 R© induces
antigen-specific T cell responses in monkeys and humans [40]. An application
of IC31 R© in combination with a commercial, MF59-based subunit vaccine
has been suggested, especially in immunosenescent mice: A better immune
response was detected, when the vaccine was combined with IC31 R©, than
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with the original vaccine [40].
IC31 R© signals via TLR9 and MyD88, as suggested by experiments us-
ing knock-out mice [42]. Recently, it was demonstrated that IC31 R© only
activates a minor fraction of peripheral dendritic cells, without diffuse pro-
inflammatory reactions. Only DCs, which directly interact with IC31 R© were
shown to upregulate CD40, CD80 (B7.1), CD86 (B7.2) and IL12p40 [30].
KLK is thought to function as a delivery vector of ODN1a, and potentially
also of antigen, acting through a series of conformational changes in its sec-
ondary structure to cross the plasma membrane of target cells (M. Aichinger,
personal communication).
Given the promising results obtained so far, the question addressed in
this thesis was, whether the adjuvant IC31 R© is also suitable in the mucosal
context. Using the model antigen CopN of Chlamydia pneumoniae, it could
be demonstrated that intranasal administration of protein antigen in combi-
nation with IC31 R© resulted in significant cellular responses.
Another adjuvant used here was cholera toxin (CT) or CT B subunit
(CTB). CT is an enterotoxin produced by Vibrio cholerae, composed of an
enzymatically active A subunit and a B subunit, that interacts with the
GM1 ganglioside expressed on host cells [17]. Once inside a host cell, the
A subunit ultimately leads to eﬄux of Cl− and osmotic movement of water
into the gut lumen, resulting in watery diarrhea. The B subunit, however, is
nontoxic [22].
CT is considered to be the “gold standard” mucosal adjuvant, but causes
high toxicity in humans [19]. On the other hand, CTB is used as an adjuvant
in the Dukoral R© (VBL Vaccin) cholera vaccine licensed for humans.
CpG1826 is a synthetic oligodeoxynucleotide containing unmethylated
CpG motifs, which occur more often in bacteria than in mammals. The
immunologic effects after administration of CpG ODNs were reported to be
proliferation of B cells and secretion of ab, activation of monocytes, macro-
phages and DCs, as well as a Th1 like pattern of cytokine production [17].
Signaling depends on TLR9.
Freund’s adjuvant is a water in mineral oil emulsion with a manide
monooleate surfactant. Complete Freund’s adjuvant (CFA), which was used
for primary immunizations only, contains inactivated mycobacteria. Incom-
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plete Freund’s adjuvant (IFA), which was used for booster immunizations,
does not contain mycobacteria. Due to its high reactogenicity, CFA cannot
be used in humans [19].
4.4 Mucosal Immunity in the Lung and Mucosal Vac-
cines
80% of immunocytes are accumulated in, or in transit between various mucosa-
associated lymphoid tissues (MALT) in the healthy adult [22], illustrating
the large area of contact between the mucosal immune system and the outer
world, as well as the resulting importance of an active, intact barrier.
Unlike the intestinal mucosa, the lung, particularly the lower respiratory
tract, is sterile in healthy humans [26]. This may seem surprising, given the
permanent exposure to environmental toxins, allergens and pathogens. The
upper airways contain intraepithelial DCs and lamina propria DCs, whereas
the lower respiratory tract contains lamina propria DCs and alveolar DCs.
The lungs are an example of type I mucosal surfaces, which are covered by
a simple epithelium. Type I mucosal surfaces express polymeric Ig receptor
(pIgR), which allows passage of secretory IgA into the lumen.
Mucosal DCs generally avoid secretion of proinflammatory cytokines,
suppressing Th1 differentiation and preferably induce a Th2/Th3 type of
response [19]. Furthermore, mucosal surfaces have a tendency towards in-
duction of tolerance, when ag is administered without adjuvant.
The motivation to pursuit research in the field of mucosal vaccination
reflects the fact, that most human pathogens gain entry through mucosal
sites [13, 18]. Hence, the idea to prime an immune response using the same
route as the pathogen only seems logical. A successful mucosal immune
response abrogates initial entry of the pathogen beyond the defensive barriers
of the host [17], whereas a systemic immunization approach could only act
at a later stage.
In addition to the the effect mentioned above, this list summarizes more
advantages of mucosal - and particularly intranasal - vaccines. [17, 18,22]:
- Both mucosal and systemic immunity can be attained.
- Increased stability and shelf-life.
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- No need for needles and specifically trained personnel.
- Improved safety for the vaccinator and vaccinee.
- Decreased or eliminated injection site pain.
- Easier and faster vaccine delivery.
- Mucosal administration frequently requires less ag and fewer doses than
does parenteral immunization. This could be of particular relevance,
when the demand for a vaccine exceeds manufacturing capabilities, as
in a pandemic.
- Immunity through intranasal immunization is intimately associated
with vaginal immunity. This might be a feasible way of immunizing
against sexually transmitted diseases.
An example of a vaccine that is applied intranasally is FluMist R© (Med-
Immune). FluMist R© is a live, cold-adapted, trivalent influenza vaccine, ad-
ministered via a prefilled single-use device that sprays the vaccine into the
nostrils [18].
4.5 A brief note on the mouse model
Mice, rabbits and monkeys were tested for susceptibility against Cpn [31]. It
was found that mice are most susceptible to infection.
Specifically, primary challenge of BALB/c mice resulted in a self-restricted
infection [37]. No culturable bacteria could be detected by day 27 after in-
fection. Interestingly, a CD4+ CD8+ double-positive population of T cells
appeared after primary challenge, which was more apparent after rechallenge.
The two mouse strains used here were BALB/c and C57BL/6. It has
been reported, that BALB/c mice preferentially develop a Th2 response
and are more susceptible to infection of intracellular pathogens, compared
to C57BL/6 mice [11]. Experimental infection with the intracellular para-
site Leishmania major caused a protective, Th1-driven response in C57BL76
mice, whereas BALB/c mice developed a non-protective Th2 response. This
might be due to a greater population of CD4+CD25+ regulatory T cells found
in BALB/c mice.
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5 Results
5.1 CopN peptide library screening
The library used here covered the entire sequence of CopN. The individual
peptides were 15-mers with an overlap of 10 amino acids. Thus, for a 399
amino acid protein, this gave rise to 78 peptides. According to the position
in the synthesis plate, the peptides were systematically designated as A1,
A2, A3 . . . A12, B1, B2, . . . until the last peptide G5.
Groups of mice were immunized three times with CopN whole protein
+ IC31 R©(100/4), protein alone, adjuvant alone or left naïve. Initially, the
strong adjuvant CFA/IFA was also used.
The IC31 R©-containing vaccine formulation was analyzed in terms of
protein-adjuvant binding behavior using a micro-bicinchoninic acid assay as
well as a HPLC-analysis. Both methods yielded similar results, indicating
that 60% of CopN were bound to IC31 R©, while 40% remained unbound.
Screening was based on an IFN-γ ELISpot with the individual peptides as
recall stimuli. Data for BALB/c mice was obtained from 3 independent sets of
animals. Screening with the entire peptide library was performed 5 times. For
the first two sets of animals, the immunization route was intraperitoneally,
whereas for the last set of animals it was subcutaneously.
A representative example of a single round of screening is given in Figure
1 for BALB/c and in Figure 2 for C57BL/6 mice. For BALB/c mice, signals
from peptides B8 and E8 appeared in each screening round for IC31 R© adju-
vanted protein administrations, while absent in control groups. For C57BL/6
mice, D10 and E11 gave the most apparent signal. At this point, no irrele-
vant peptide controls were used, because the library itself contained irrelevant
peptides.
CFA/IFA-adjuvanted protein administrations (not shown) resulted in a
general increase of average peptide-signal. The main rationale for includ-
ing this treatment was to have another adjuvant in case there is no effect
in IC31 R©-adjuvanted groups. Interestingly, adjuvantation of CopN with
IC31 R© gave dominant signals for e.g. peptides B8 and E8, while correspond-
ing signals were significantly lower or even not detectable in the case of
CFA/IFA. However, this might as well be due to a trend towards over-
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Figure 1: IFN-γ ELISpot screening in BALB/c mice. A, B, C: Animals were immunized
3 times at day 0, 14 and 28. D: PBS-mock-immunized. On day 42, mice were sacrificed.
Concentration of peptides was 10 µg/mL. SFC extrapolated to 1x106 total spleen cells.
Mean ± SD. Similar results were obtained in 2 independent experiments
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Figure 2: IFN-γ ELISpot screening in C57BL/6 mice. A, B, C: Animals were immunized
3 times at day 0, 14 and 28. D: untreated. On day 42, mice were sacrificed. Concentration
of peptides was 10 µg/mL. SFC extrapolated to 1x106 total spleen cells. Mean ± SD.
Similar results were obtained in 2 independent experiments
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Name Sequence Candidate in
A3 GGTQGVNLAAVEAAA BALB/c
B6 ESTEEKPDTDLADKY BALB/c
B7 KPDTDLADKYASGNS BALB/c
B8 LADKYASGNSEISGQ BALB/c
C8 SQGKLKEALIQARNT BALB/c
D8 TCDQLLSMLQDRYTY BALB/c
E8 SYDYFESRVPILLDS BALB/c
F3 YHKIINDKFPTASKV BALB/c
F8 DVDSVTGVLNLFFSA BALB/c
F9 TGVLNLFFSALRQTS BALB/c
F11 LRQTSSRLFSSADKR BALB/c
G3 MIANALDAVNINNED BALB/c
A5 VEAAAAKADAAEVVA C57BL/6
D10 DRYTYQDMAIVSSFL C57BL/6
E10 ILLDSLKAEGIQTPS C57BL/6
E11 LKAEGIQTPSDLNFV C57BL/6
D11 QDMAIVSSFLMKGMA BALB/c + C57BL/6
F10 LFFSALRQTSSRLFS BALB/c + C57BL/6
Table 2: Summary of candidate epitopes for both BALB/c and C57BL/6.
stimulation in the latter case.
Since the purpose of this screening approach was to get a quick yes/no
answer as to whether a certain peptide is an immunogenic epitope or not, a
simple criterion was established: If the mean of the peptide-specific signal
obtained in the ELISpot was greater or equal than the double mean from
the medium-specific signal, the counter of this peptide was incremented by
one. In addition to the automated read-out, a visual inspection was also
performed. For example, B8 is a clear candidate in terms of quantitative
IFN-γ response, whereas E8 gave rise to significantly larger spots than all
other peptides, indicating a difference in the quality of response.
After successive rounds of screening, it was apparent which peptides could
be considered as candidates and which peptides could be regarded as non-
immunogenic under these conditions. Table 2 summarizes the findings of the
screening experiments. There were 12 candidate epitopes in BALB/c mice,
4 in C57BL/6 and 2 shared epitopes.
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Name Sequence
B8 LADKYASGNSEISGQ
B8.1 KYASGNSEI
B8.2 YASGNSEIS
B8.3 DKYASGNSE
E8 SYDYFESRVPILLDS
E8.1 DYFESRVPI
E8.2 YFESRVPIL
E8.3 YDYFESRVP
E8.4 SYDYFESRV
Table 3: Potential minimal epitopes of peptides B8 and E8.
5.2 Identification of minimal epitopes
The screening was performed without any in silico predictions done a priori.
However, at a certain time point the entire sequence of CopN was entered into
an online MHC-prediction server [39]. The top-scoring peptides for BALB/c
mice were also those found experimentally, i.e. B8 and E8. According to this
prediction, both 15-mers contain H2-Kd nonamers.
With these findings in mind, several potential minimal epitopes were
synthesized for B8 and E8. These 9-mers are depicted in Table 3, along with
the original 15-mers. B8.1 and E8.1 were the highest-scoring nonamers in
silico.
As can be seen in Figure 3, B8.1 and B8.2 gave a significantly higher
response than B8.3. Nevertheless, there was still a considerable amount of
IFN-γ release for B8.3 compared to medium or irrelevant peptides A5-A7,
which might indicate the presence of only one anchor residue and no sig-
nificant sterical hindrance of the remaining peptide with the MHCI-binding
pocket.
The situation was less clear for the E8-derived nonamers. According
to the data shown in Figure 3, E8.1 might be the principal nonamer. 14
days after the third immunization, similar results were obtained (not shown).
Further evidence for the relevance of peptides B8.1 and E8.1 is provided in
Section 5.7 on page 20.
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Figure 3: Identification of minimal epitopes in BALB/c mice through an IFN-γ ELISpot.
Animals were immunized two times at day 0 and 14 s.c. On day 28 mice were sacrificed.
Concentration of peptides was 10 µg/mL. A5, A6 and A7 were irrelevant peptides. SFC
extrapolated to 1x106 total spleen cells. Mean ± SD. Similar results were obtained
14 days post third immunization
5.3 Titration of minimal epitopes B8.1 and E8.1
To demonstrate the potency of these newly found minimal epitopes, as well
as to show specificity, titrations at semi-logarithmic steps were performed.
As Figure 4 demonstrates, there was a broad range of concentrations, which
caused significant IFN-γ release. Interestingly, this applied to subcutaneously
and intranasally immunized mice (Figure 4A and B, respectively), when
spleens were assessed.
Peptides 19 and 27 are irrelevant peptides, which are also H2-Kd-restricted.
In the data shown before, concentration of peptides was given in µg/mL.
Here, concentration is expressed in terms of molarity, thereby allowing di-
rect comparison between the two epitopes. Thus, there is a higher precursor
frequency of T cells specific for B8.1 than for E8.1, in agreement with the in
silico prediction score.
5.4 CD4/CD8 restriction of candidate peptides
To find out, whether the candidate peptides defined in BALB/c and C57BL/6
mice are CD4 or CD8 epitopes, the following experiment was made: Spleen
cells from immunized animals were split into three aliquots. The first was
used as is (termed whole suspension), the second aliquot was depleted of
CD8+ T cells and the third was depleted of CD4+ T cells. Depletion was
chosen to avoid the possibility of unspecific stimulation, which could be an
effect of positive selection after direct labeling of CD4 or CD8.
15
Figure 4: IFN-γ ELISpot: Titration of minimal epitopes B8.1 and E8.1 in BALB/c mice.
Animals were immunized three times at day 0, 14 and 28 s.c. or i.n. On day 42 mice were
sacrificed. Concentration of irrelevant peptides 19 and 27 was 10 µg/mL. SFC extrapolated
to 1x106 total spleen cells. Mean ± SD. Comparable results were obtained in an
independent experiment.
The results of this isolation approach are depicted in Figure 5. According
to these data, B8 and B8.1 as well as E8 and E8.1 are CD8-restricted epitopes
(Figure 5A). In the second experiment performed with BALB/c mice there
were minor signals originating from CD4+CD8- cells for A3, B6, B7 and F3
(not shown).
In C57BL/6 mice, A5, D10 and D11 might be CD4-restricted epitopes
(Figure 5B).
The purity of the isolated cells was assessed via a FACS analysis as de-
picted in Figure 5C.
5.5 Analysis of isolated lung T cells
Data shown so far originated from spleen cells. Already it was seen, that
intranasal administration could elicit a splenic response (Figure 4B). In this
section, also lung T cells will be discussed.
In analogy to the isolation approach mentioned in section 5.4, the prin-
ciple of untouched isolation was also followed here. This time on lung T
cells, however. Non-T cells (i.e. B cells, NK cells, dendritic cells, macropha-
ges, granulocytes and erythroid cells [1]) were labeled and retained, enabling
further analysis of the unlabeled T cells.
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Figure 5: IFN-γ ELISpot: CD4/CD8 restriction of candidate peptides in BALB/c and
C57BL/6 mice. Animals were immunized three times at day 0, 14 and 28 as shown. On
day 42 mice were sacrificed. Concentration of peptides was 10 µg/mL. Peptides 19 and
27 are irrelevant peptides. B: *indicates, that the signal exceeded the upper detection
limit. SFC extrapolated to 1x106 total spleen cells. Mean ± SD. Similar results were
obtained in an independent experiment for BALB/c mice. C: Flow cytometric
analysis demonstrating cell purity of cells after isolation, which were used in A
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Consequently, a source of antigen presenting cells must be supplied.
Spleen cells from naïve mice were used, either without any treatment or
after an irradiation step.
Figure 6A and B shows the lung T cell response of BALB/c and C57BL/6
mice. Most candidate peptides identified via the screening of spleen cells
from mice immunized with CopN parenterally were also recognized by lung
T cells from mice immunized with CopN by mucosal immunization. No
signals were obtained in control groups which were immunized with CopN
alone, IC31 R© alone or left naïve (not shown).
In particular, the IFN-γ signal in response to the minimal epitopes B8.1
and E8.1 was significantly higher here than in spleen cells from parenter-
ally immunized mice (Figure 6A). Interestingly, the signal for peptide E8,
which was always lower than B8 when spleen cells were assessed, reached a
comparable value in this context (reproduced in an independent experiment).
To have a means of comparison for the mucosal administration of IC31 R©,
BALB/c mice were also immunized with a CopN formulation adjuvanted with
CTB or CpG1826. The response to selected epitopes is depicted in Figure 6C.
In the case of IFN-γ response to peptides, IC31 R© outperformed CpG1826. A
significant difference between CTB and IC31 R© was only apparent for peptide
B8.
The mucosal response for C57BL/6 mice was of lower intensity (6B. Still,
peptide D10 was readily detectable, while other peptide candidates showed
a lower response.
The purity of lung T cells is depicted in Figure 6D. Before lung T cell
isolation there were circa 40% CD4−CD8− events in the FSC/SSClymphocyte
gate. These events dropped to circa 3% after isolation.
5.6 Comparison of subcutaneous and intranasal immu-
nization
The data shown so far comprised analysis of spleen cells from parenterally
or intranasally immunized mice, as well as lung T cells from intranasally
immunized mice. A remaining question is, whether parenteral immunization
could also elicit a lung T cell response.
The data shown in Figures 7 and 8 shows all four different combinations
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Figure 6: IFN-γ ELISpot using isolated lung T cells. Animals were immunized 3 times
at day 0, 14 and 28 i.n. On day 42, mice were sacrificed. Concentration of peptides
was 10 µg/mL. Ovalbumin was chosen as an irrelevant protein. Peptides 19 and 27 are
irrelevant peptides. C: Comparison between IC31 R©, cholera toxin B and CpG1826. D:
Demonstration of increased purity of lung T cells after isolation. Refer to text for details.
SFC extrapolated to 1x106 total lung T cells. Mean ± SD. Similar results were
obtained in one independent experiment
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Administration of CopN Epitope pentamer+ cells [%]
Spleen cells Lung cells
IC31 R©(100/4) s.c. B8.1 0.23 0.03
IC31 R©(20/0,8) i.n. B8.1 0.13 0.47
IC31 R©(100/4) s.c. E8.1 0.14 0.05
IC31 R©(20/0,8) i.n. E8.1 0.13 0.24
Table 4: CD8+ T cell-specific probes for BALB/c mice. Animals were immunized 3
times at day 0, 14 and 28. On day 44, mice were sacrificed. Events shown here were gated
from a FSC/SSClymphocytes and a CD8high population. A background subtraction using
signal obtained from a CopN-immunized control group was performed. A similar trend
was observed in an independent experiment for spleen cells.
of administration route and organ assessed in BALB/c and C57BL/6 mice,
respectively. It entails the lung T cell data shown in Figure 6.
There is some evidence, that subcutaneous immunization causes almost
no priming of lung T cells in BALB/c mice, although a response could be
detected in C57BL/6 mice. The observation, that intranasal immunization
caused a splenic response was already discussed for BALB/c mice. Figure
8 suggests that it might also be true for C57BL/6 mice. Finally, it is also
noteworthy that the magnitude of the lung T cell response after intranasal
immunization was significantly greater in BALB/c than in C57BL/6 mice.
5.7 CD8+ T cell-specific probes
The use of CD8+ T cell-specific probes has become an accepted method for
accurate quantification of precursor frequencies [6, 35, 47]. The probes used
here consisted of a pentameric complex of H2-Kd MHC class I molecules,
connected though a coiled-coil domain to a fluorescent compound [2], which
was allophycocyanin (APC). Due to the high costs of these reagents, only
two pentamers were purchased for the most promising epitopes of BALB/c
mice.
The data shown in Figure 9 shows the precursor frequencies of B8.1-
and E8.1-specific lung T cells. It is apparent that lung T cells from mice
immunized with CopN adjuvanted with IC31 R© had higher levels of epitope-
specific cells than those from control groups.
Among the control groups, the number of specific CD8+ T cells was
higher in CopN immunized animals than the other two. Exact percentages
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Figure 7: IFN-γ ELISpot: Combinations of administration route/organ assessed in
BALB/c mice. Animals were immunized at day 0, 17 and 31. On day 46, mice were
sacrificed. Concentration of peptides was 10 µg/mL. Peptides 19 and 27 are irrelevant
peptides. SFC extrapolated to 1x106 spleen cells or total lung T cells. Mean ± SD.
A: *indicates, that the signal exceeded the upper detection limit. Similar results
were obtained in at least one independent experiment, despite for the combination
i.n./spleen cells
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Figure 8: IFN-γ ELISpot: Combinations of administration route/organ assessed in
C57BL/6 mice. Animals were immunized at day 0, 17 and 31. On day 46, mice were
sacrificed. Concentration of peptides was 10 µg/mL. Peptides 19 and 27 are irrelevant
peptides. SFC extrapolated to 1x106 spleen cells or total lung T cells. Mean ±
SD. A: *indicates, that the signal exceeded the upper detection limit. Similar
results were obtained in one independent experiment, despite for the combination
i.n./spleen cells
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Figure 9: CD8+ T cell-specific probes for BALB/c mice. Animals were immunized 3
times at day 0, 14 and 28. On day 44, mice were sacrificed. Events shown here were gated
from a FSC/SSClymphocytes and a CD8high population. A similar trend was observed in
an independent experiment for spleen cells.
of background-corrected precursor frequencies are given in Table 4. Interest-
ingly, subcutaneous application resulted in a considerable signal from spleen
cells, but a negligible signal from lung T cells. On the other hand, intranasal
application resulted in a considerable signal in lung T cells as well as in spleen
cells.
In order to compare the percentages of specific T cells shown in Table
4 with ELISpot data, it is necessary to refer to the percentages to T cells
instead of CD8+ T cells. Previous experiments showed that there are ca. 25%
of CD8+ and 75% of CD4+ T cells in BALB/c mice (not shown). Bearing
this factor in mind, there were more pentamer+ cells than IFN-γ releasing
cells, as anticipated.
Specifically, the ratio of pentamer+ cells and IFN-γ-releasing cells was
higher in subcutaneously immunized animals than in intranasally immunized
animals.
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5.8 Single dose immunization with CopN
The results shown so far originated from animals immunized three times.
This section discusses single-dose administration on CopN whole protein ad-
juvanted with IC31 R© or CpG1826.
Figure 10 suggests that IFN-γ release was detected after a single immu-
nization of CopN at the base of the tail in BALB/c and C57BL/6 mice. As
anticipated, the T cell precursor frequency observed here was lower than in
animals which received three immunizations. Remarkably, peptide E8 was
readily detectable when adjuvanted with IC31 R©, but not with CpG1826.
This has also been observed in the intranasal administration of CopN.
A similar principle might apply for peptide D10 in C57BL/6 mice: It
could be detected when IC31 R© was used as adjuvant, but not when CpG1826
was used.
5.9 Immunizations with candidate peptides
A relevant question is, whether peptide immunizations could also prime a
detectable amount of specific T cells. Whereas up to now, immunizations
were performed with 40 µg of CopN per dose, here 50 nmol of peptide were
used. Due to the large amount of peptide required, only the top two peptides
per mouse strain were used.
Results are depicted in Figure 11. Peptide E8 in BALB/c and D10 in
C57BL/6 mice were able to prime enough T cells in order to detect them
by means of an IFN-γ ELISpot. The apparent lack of signal in the case of
B8 and E11, however, might suggest the need of a CD4 helper epitope [28,
38]. Another possible explanation might be, that impurities in the peptide
synthesis acted as altered peptide ligands, promoting anergy instead of IFN-
γ-releasing T cells [43].
5.10 IFN-γ response at later time points
A crucial aspect in vaccine development is the induction of memory T cells,
which can exert protective functions long after vaccination. As a first step
in this direction, IFN-γ response at time points later than 14 days after the
third immunization were assessed.
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Figure 10: IFN-γ ELISpot after single dose immunization with CopN in BALB/c and
C57BL/6 mice. Animals were immunized at day 0 at the base of the tail. On day 8, mice
were sacrificed. Concentration of peptides was 10 µg/mL. Peptides 19 and 27 are irrelevant
peptides. SFC extrapolated to 1x106 spleen cells. Mean ± SD. This experiment was
only performed once
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Figure 11: IFN-γ ELISpot after two immunizations with peptide in BALB/c and
C57BL/6 mice. Animals were immunized at day 0 and 6 at the base of the tail with
50 nmol of peptide. On day 13, mice were sacrificed. Concentration of peptides was 10
µg/mL. Peptide 27 is an irrelevant peptide. SFC extrapolated to 1x106 spleen cells.
Mean ± SD. This experiment was only performed once
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Figure 12: IFN-γ ELISpot at later time points in BALB/c and C57BL/6 mice. Animals
were immunized at day 0, 14 and 28. Mice were sacrificed at three time points as indicated.
Concentration of peptides was 10 µg/mL. Peptides 19 and 27 are irrelevant peptides. C:
*indicates, that the signal exceeded the upper detection limit. SFC extrapolated to 1x106
spleen cells. Mean ± SD. Data from day 42 and 99 was only obtained in one
experiment.
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Figure 13: cultured IFN-γ ELISpot after Chlamydia pneumoniae infection in BALB/c
and C57BL/6 mice. Animals were infected intranasally at day 0 and 27 (A) or 29 (B).
Mice were sacrificed 12 days later. Concentration of stimuli was 10 µg/mL during the 48
hours culture, and half of this concentration during the ELISpot. SFC extrapolated to
1x106 cultured spleen cells. Mean ± SD. Data for BALB/c was only obtained in
one experiment. A similar trend was observed for C57BL/6 in one independent
experiment
In BALB/c mice, the minimal epitopes B8.1 and E8.1 could still be easily
detected at the latest time point, irrespective of subcutaneous or intranasal
application (Figure 12A and B). Once again this elegantly demonstrates the
experimental advantage of minimal epitopes.
In BALB/c mice, intranasal immunization caused a greater response of
spleen cells on day 56 than on the other time points. This might reflect the
migration of locally primed T cells to central organs such as the spleen. On
the other hand, data at this time point was only assessed once.
It was also tried to obtain data from lung T cells at these later time
points. This was not possible due to overstimulation of cells.
5.11 Priming of T cells during a Chlamydia pneumo-
niae infection
The data shown so far was obtained by immunizing mice with CopN whole
protein or candidate peptide, mostly adjuvanted with IC31 R©. The evident
question is whether reactivity towards CopN is of relevance during a Chlamy-
dia pneumoniae infection. In other words: can a natural infection prime T
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cells specific for CopN?
To solve this question, a cultured IFN-γ ELISpot was performed. After
obtaining spleen cells from infected mice, these cells were incubated for circa
48 hours prior to the IFN-γ ELISpot. During this incubation period, the
same stimuli were used as in the following ELISpot. This has the effect of
amplifying small T cell populations, which could not be detected in an ex
vivo ELISpot as performed before.
Figure 13 shows the outcome of this approach. A strong signal was ob-
tained for CopN in both strains. Interestingly, signal for candidate peptide
E11, which did not produce a strong signal in previous experiments, was
slightly elevated compared to other peptides in C57BL/6 mice, indicating a
particular role of E11 during an infection.
The signal for CopN may seem promising, however at this point it must
be stated that a necessary control is missing: An aliquot of cells that was
treated with CopN during the 48 hours culture should have been stimulated
with an irrelevant protein control like Ovalbumin in the IFN-γ ELISpot. A
similar control was performed with Ovalbumin also being present during the
culture. The obtained signal was lower than for CopN (not shown), but this
approach might not be a true irrelevant control.
It was also tried use the pentamers specific for B8.1 and E8.1 on a short
term line from reinfected animals. No significant signals could be obtained
(not shown), in agreement with the data from the cultured IFN-γ ELISpot.
5.12 In vivo cytotoxicity assay
The major functional response assessed so far has been the release of IFN-γ.
However, the ultimate ability of CD8+ T cells is to lyse target cells, which
display a non-self epitope.
In an in vivo cytotoxicity assay, this ability can be measured. Naive spleen
cells were incubated with a particular epitope and labeled with a fluorescent
dye. These cells were then mixed with reference cells which were incubated
with buffer only and labeled with a lower concentration of fluorescent dye.
In the experiment performed here, the cells were administered intranasally
to immunized and infected animals, along with control groups. Due to
the complexity of the experiment, only the top two peptide candidates for
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Figure 14: In vivo cytotoxicity assay: target cells for BALB/c mice before they were
administered. Events shown here were gated from a FSC/SSClymphocytes and a CFSEhigh
population.
BALB/c mice were used. The fluorescent signal from these target cells before
administration is depicted in Figure 14.
18 hours after administration, lungs were obtained from individual mice
and measured as before. It was anticipated, that the number of cells which
were pulsed with peptide decreases relative to the medium-control cells. No
significant difference could be detected between infected or immunized and
control groups (not shown). Possible explanations are discussed on page 38.
5.13 CD154 assay: Activation of helper T cells
CD154, also known as CD40L, is expressed by helper T cells activated by
antigen and costimulators. CD40-CD40L interaction is involved in direct cell
contact between helper T cells and B cells or macrophages, providing cos-
timulatory signals [5]. Because CD154 is specifically upregulated on recently
activated cells, it can be used as an activation marker [10, 16].
Data in Figure 5 suggested the presence of CD4-restricted epitopes in
C57BL/6 mice. As can be seen in Figure 15, there was a CopN-dependent up-
regulation of CD154 compared to medium alone in mice that were immunized
with CopN + IC31 R© subcutaneously. Furthermore, increase in background-
corrected CD154 expression could not be detected in control groups, which
received CopN alone or IC31 R© alone.
A specific upregulation of CD154 was not observed in reinfected mice
compared to naive mice. However, it was not attempted to perform a pre-
culture prior to the assay, which might amplify an existing helper T cell
population specific for CopN, in a similar fashion as in Figure 13.
Increase in CD154 could not be observed in BALB/c mice, in agreement
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Figure 15: CD154 assay: Activation of helper T cells in C57BL/6 mice. Animals were
immunized 3 times at day 0, 14 and 28 with CopN + IC31 R©(100/4) subcutaneously. On
day 42, mice were sacrificed. The stimuli during the incubation are shown on top of each
dot blot. SEB served as a positive control. 6x104 events in the FSC/SSClymphocytes
gate were collected. Events shown here were gated from a FSC/SSClymphocytes and
a CD4high population. This experiment was only performed once.
with the preponderant CD8 restriction of epitopes.
5.14 CD107 mobilization assay: Activation of CD8+
cells
CD107 is present in the membrane of pre-formed cytotoxic granules inside
CD8+ T cells. Soon after recognition of antigen, activation-induced degran-
ulation occurs, releasing cytotoxic compounds like perforin and granzyme.
The exposure of the CD107 marker provides an indication of the cytotoxic
potential of the responding CD8+ T cells [7, 34].
The CD107 mobilization assay was attempted in five independent ex-
periments, but no positive signal was obtained. Cells used originated
from peptide-immunized mice, infected mice and cells from a short-term
line. Signals for the following positive controls were obtained, in decreas-
ing magnitude: concanavalin A, Staphylococcus aureus enterotoxin B and
PMA/ionomycin (not shown). A detailed discussion of possible reasons is
given on page 39.
5.15 Linear B cell epitope screening
As a side project, the peptide library was also used to perform a linear B
cell epitope screening. Individual peptides were spotted on a membrane,
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Figure 16: Linear B cell epitope screening. Serum was obtained from terminal bleedings.
Circa 20 µg of peptide were spotted on a PVDF membrane. C: LPS content was ca. 14500
EU/mg during the first immunization and ca. 4500 during the subsequent immunizations.
D: LPS content was 21 EU/mg at all three immunization. Similar results were obtained
for B in one independent experiment.
which was then incubated with serum obtained from terminally bled animals
followed by a colorimetric reaction.
As can be seen in Figure 16, there were several spots that differed between
immunized, reinfected and the naïve group. There was a faint signal for
peptide E7 that appeared in immunized and reinfected groups, but not in
naïve. Peptide F5 only appeared in the CFA/IFA-immunized group, not in
naïve or IC31 R©-adjuvanted groups.
A pronounced signal was peptide B2. It appeared in immunized groups,
but not in naïve or infected groups. Although antibodies against B2 might
not be generated in a natural infection, they might still be involved in rec-
ognizing live bacteria.
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Figure 17: Immunofluorescence microscopy of cells infected with Chlamydia pneumonia:
HEp-2 cells were grown on coverslips in 24-well plates. They were infected with Chlamydia
pneumoniae K6 and incubated for 72 hours. Then, they were incubated with mouse
serum and a rabbit antibody specific for the inclusion membrane. Serum in A and B
was from BALB/c mice immunized with CopN + IC31 R©(100/4) i.p. A: LPS content was
ca. 14500 EU/mg during the first immunization and ca. 4500 EU/mg during subsequent
immunizations. B: LPS content was ca. 4500 EU/mg during the first immunization and
21 EU/mg during subsequent immunizations. Green signal: AF488-conjugated goat anti-
mouse Ig. Red signal: AF594-conjugated goat anti rabbit IgG. Nuclei were stained with
DAPI (blue).
5.16 Immunofluorescence microscopy of cells infected
with Chlamydia pneumoniae
The serum obtained from immunized animals was also used to stain infected
cells. Thereafter, a fluorochrome-labeled anti-mouse secondary antibody was
used.
Interestingly, detection of Chlamydia pneumonia was only possible with
serum from animals immunized with CopN + IC31 R©, where CopN had a high
LPS content (Figure 17A). Animals immunized under similar conditions,
where only the batch of CopN differed, did not produce serum capable of
staining bacterial structures (Figure 17B). Moreover, animals which were
immunized with CopN high LPS without adjuvant produced serum which
stained Chlamydia pneumonia, if a high exposure time was set. Serum from
animals immunized with IC31 R© only or naïve did not stain infected cells (not
shown).
5.17 ELISA of serum from immunized animals
Figure 18 depicts the results of an ELISA against whole IgG. Reminiscent of
the Immunofluorescence microscopy experiments, there was a LPS-dependent
behavior (Figure 18A and B).
Serum from BALB/c mice immunized with CopN + IC31 R©(100/4) i.p.
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Figure 18: ELISA of serum from immunized animals. Mice were immunized three times
at day 0, 14 and 28 as depicted. Mice were terminally bled at day 42. A: LPS content was
ca. 14500 EU/mg during the first immunization and ca. 4500 EU/mg during subsequent
immunizations. B and C: LPS content was ca. 4500 EU/mg during the first immuniza-
tion and 21 EU/mg during subsequent immunizations. * below limit of detection. Data
obtained from non-linear regression with constrained bottom of blank-subtracted means
from photometric readouts. Mean ± 95% CI.
showed a comparable IgG titer as mice immunized with CFA/IFA only when
CopN with high amounts of LPS was used. The titer dropped by one order
of magnitude when CopN with low LPS contamination was used. This effect
was even more apparent in the more Th1-tilted C57BL/6 strain.
Because the focus of this thesis was more on the T cell response to ad-
ministrations of IC31 R©, this issue was not followed up.
5.18 Microarray analysis of total RNA from lung T
cells
In order to identify factors, which are differentially regulated during in-
tranasal administration of CopN + IC31 R© in lung T cells, a microarray
experiment was performed. Freshly isolated lung T cells from immunized
and control mice were homogenized and total RNA was isolated.
In this trial experiment, only BALB/c mice were chosen. Mice received
CopN + IC31 R©(20/0.8), CopN only or were left naïve. Purity of the isolated
RNA was assessed photometrically. Values for A260/A280 were above 2 and
values for A260/A230 were above 1.7, indicating negligible protein and salt
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Figure 19: Non-denaturing agarose gel of total RNA from freshly isolated lung T cells
from BALB/c mice. A RNeasy Midi isolation kit (Qiagen) was used to isolate RNA after
MACS. 1 µg of RNA was loaded onto a 1.2% agarose gel. The marker (M) used here was
only of internal use.
contaminations, respectively.
Furthermore, a non-denaturing gel was run to detect potential degrada-
tion events. According to Figure 19, no degradation occurred. The upper
two bands might correspond to 28 and 18S rRNA. The lowest band might
be 5S rRNA.
Microarray analysis of RNA was performed by SABiosciencesTM . The
array covered mouse inflammatory cytokines and receptors. A list of probes
which were sampled is given in the appendix on page A.
Candidate genes which were significantly up- or downregulated in the
sample group CopN + IC31 R©(20/0.8 i.n.) compared to both control groups
(CopN i.n. or naïve) were further analyzed. The cellular source and main
function of a given gene were assessed individually in the Cytokines & Cells
Online Pathfinder Encyclopaedia [3], Online Mendelian Inheritance in Man
[4] or in a textbook [5]. Table 5 shows differentially regulated mRNA known
to be expressed in T cells. A discussion is given on page 39.
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Upregulated
Name GeneBank
Interferon alpha 2 NM_010503
Interleukin 12B NM_008352
Downregulated
Name GeneBank
Chemokine (C-C motif) ligand 5 NM_013653
Interferon gamma NM_008337
Interleukin 10 NM_010548
Interleukin 10 receptor, beta NM_008349
Interleukin 18 NM_008360
Interleukin 1 beta NM_008361
Interleukin 3 NM_010556
Integrin beta 2 NM_008404
Secreted phosphoprotein 1 NM_009263
Tumor necrosis factor NM_013693
Table 5: Microarray analysis of total RNA from lung T cells: Genes up- or downregulated
in sample group compared to control groups. Refer to text for more information.
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6 Discussion
The data shown here demonstrate encouraging effects of the adjuvant IC31 R©
on mucosal immunity in the murine system. Specifically, intranasal admin-
istration of the whole protein CopN in combination with IC31 R© resulted in
local and systemic immune responses, as determined via IFN-γ ELISpot of
lung T cells and spleen cells, respectively.
Preceding these findings, immunogenic epitopes of CopN were identified.
Using a purely experimental approach avoids the risk of missing peptides,
which could be identified as false negatives in silico. However, the design
of the peptide library had a bias towards CD8-restricted epitopes: Peptides
presented on MHC class I have a relatively narrow size distribution of 8-11
amino acids (rare exceptions exist, though), whereas peptides displayed on
MHC class II can be between 10-30 amino acids or even longer [5, 33]. The
peptides used for the screening were 15-mers. Furthermore, only IFN-γ and
no Th2 cytokine was used during the screening.
Despite these obvious limitations, attractive candidate epitopes were sug-
gested here, among which B8.1 and E8.1 were the most promising in BALB/c
mice. Here, further evidence was also provided by using MHCI pentamers.
Both B8.1- and E8.1-specific CD8+ T cells could be detected in lungs and
spleens from animals immunized i.n.
Titration experiments suggested, that more T cells are primed for B8.1
than for E8.1. In silico predictions, which base their calculations on the
affinity of individual amino acids to the MHC, yielded the same ranking. In-
terestingly, it has been described that peptide affinity towards MHC directly
correlates with immunogenicity [43].
A follow-up experiment would be to test the potential minimal epitopes
B8.2-3 and E8.2-4 also at lower concentrations, because they gave responses
significantly above medium background. If other sites are reproducibly shown
to be immunogenic, this immunogenic “hot spot” might be interesting from a
sequence conservation point of view: Should a population be immune due to
exquisite recognition of a single epitope, a pathogen could rapidly mutate and
evade immune recognition. However, should a population be able to recognize
multiple neighboring epitopes, the probability for the pathogen to mutate
both of these epitopes in one generation, while maintaining a functional gene
37
product, is very low. The necessity of Cpn to maintain a functional CopN
was already demonstrated by Huang et al. using a functional knock-out of
CopN [24].
Direct comparison of IFN-γ SFCs among lung T cells from animals im-
munized with CopN and IC31 R©, CTB or CpG1826 gave interesting results:
Signals from IC31 R© were, with the exception of B8, stronger than signals
from the “gold standard” CTB. With the exception of CopN whole protein,
IC31 R© always performed equal or better than CpG1826.
A potentially interesting observation was, that the ratio of pentamer+
cells and IFN-γ-releasing cells was higher in subcutaneously immunized an-
imals than in intranasally immunized animals. An intriguing FACS-based
follow-up experiment might be to take multiple cytokines into account. I.n. ad-
ministration might preferably induce effector T cells compared to parenteral
administration, which might induce a broader repertoire of cytokine secre-
tion.
According to preliminary results, s.c. immunization caused almost no
priming of lung T cells in BALB/c mice, while IFN-γ release was detectable
in C57BL/6 mice. As mentioned in the introduction, this might be an effect
of the preference of C57BL/6 mice to mount a Th1-type of reaction. On
the other hand, i.n. administration in BALB/c mice caused a significantly
stronger priming of lung T cell than in C57BL/6 mice.
An encouraging result was the detection of CopN-specific cells during a
Cpn infection. This is in agreement with the data shown by Tammiruusu
et al. [50]. The logical follow-up would be to detect a reduction in bacterial
load in immunized vs. control groups. Furthermore, an optimized protocol
for obtaining short-term lines might also detect candidate epitope-specific
Cpn-primed T cells.
A functional assay that was attempted here was the in vivo cytotoxicity
assay. Unfortunately, no specific killing was observed, which is likely due to
wrong assay conditions. The two most critical parameters in this context
might be the choice of peptide and the incubation period.
Here, 15-mers (B8 and E8) were used. However, other papers reporting
this method used minimal epitopes, mostly nonamers [8]. Thus, a repetition
with B8.1 and E8.1 might yield a better result.
38
Furthermore, the incubation period used here was 18 hours, as reported
previously [51]. However, it has been shown that killing can occur as early
as 15 minutes after administration of labeled cells [8], in agreement with the
observation that target cell death occurs within 5 minutes of CTL-target cell
contact [46]. Thus, assessment of killing at multiple earlier time points might
also be feasible.
The fact that significant IFN-γ release was detected for B8 and E8, but
all attempts of the CD107 mobilization assay being unsuccessful raises the
question if the experimental conditions have been optimal.
First of all, only anti-CD107a has been used. Betts et al. performed
trial experiments with CD107a and CD107b and used a mixture of both
throughout the rest of their publication [7].
Second, a brighter fluorochrome like allophycocyanin might be superior
over AF488 which was used here. APC-CD107 is very likely to produce an
easily discernible CD107high population.
Third, a minor optimization might be to add the secretion inhibitor mon-
ensin one hour after incubation instead of adding it already at the beginning
of the incubation.
Finally, it might also be worth considering to lower the amount of FCS
present in the culture medium, because high levels of background-stimulation
were observed. Another optimization in this direction would be to define a
dump channel for B cells and monocytes, which were reported to contribute
significantly to non-specific background [7]. Then, all confounding CD107-
signals from these cells could easily be excluded.
Concerning the peptide-immunization experiments, no signal was ob-
tained for B8 and E11. It is possible that B8 requires the presence of CD4+
helper epitopes in order to be immunogenic [38]. Before any conclusions
are drawn, this experiment would have to be repeated, preferably with a
very pure synthesis in order to avoid tolerance induction by altered peptide
ligands [43].
Despite the initial trial character of the microarray experiment, which
awaits optimization and reproduction of results, a brief description of the
biological activities of differentially regulated factors are given here. Infor-
mation was collected from sources mentioned before [3–5].
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All known subtypes of IFN-α, including IFN-α2 shown to be upregu-
lated here, display the same antiviral, antiparasitic, antiproliferative activi-
ties, which might indicate a general effect mediated by IC31 R©.
IL-12B is part of the heterodimer IL-12, together with IL-12A. IL-12B was
shown to be upregulated, but not IL-12A. Murine IL-12 has been shown to
alter CD4+ subset differentiation. It is also involved in protective immunity
against intracellular parasitic infections such as Leishmania major. However,
IL-12B may also form homodimers, which antagonize the aforementioned
effects. Interestingly, IL-10, shown to be downregulated, is an inhibitor of
IL-12 production.
The following factors were shown to be downregulated:
Chemokine (C-C motif) ligand 5 (RANTES) is induced by TNF-α and IL-
1α, but repressed following the stimulation of T cells. RANTES is involved
in recruiting lymphocytes to inflammatory sites.
IFN-γ is mainly produced by T an NK cells in response to ag. The
main function of IFN-γ is to activate macrophages. It is also involved in
promoting a Th1-type response and repressing a Th2-type response. Secreted
phosphoprotein 1, also known as osteopontin, which was also shown to be
downregulated, is secreted by a plethora of cells, including activated T and
NK cells. It was also shown to be involved in promotion of robust Th1
responses. In close analogy, IL-18, also downregulated, functions as a growth
and differentiation factor for Th1 cells.
IFN-γ also inhibits the growth of B-cells induced by IL-4, as well the
production of IgG1 and IgE. Interestingly, also IL-12 has been shown to
inhibit production of IgE.
In monocytes and macrophages IFN-γ induces the secretion of TNF-α,
which was also shown to be downregulated here. TNF-α is intimately asso-
ciated with inflammatory responses.
Furthermore, TNF-α, along with type I and II interferons and microbial
products, induces the synthesis of IL-1. The main biological activity of IL-1
is the promotion of Th1-type responses. Low concentrations of IL-1 are as-
sociated with local inflammation, whereas high concentrations are associated
with systemic inflammation.
In summary, these initial microarray results point towards an anti-in-
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flammatory, anti-IgE state with a repression of factors that favor a Th1-type
response. It must be stressed that this is only a “snapshot” of the developing
immune response, hence interpretation must be performed carefully.
Although the findings related to mucosal administration of IC31 R© de-
scribed here might indicate significant adjuvanticity in the mouse model,
extrapolation to man must be treated with caution. It has been reported
that bronchus associated lymphoid tissue (BALT) is significantly lower or
absent in man compared to mice [21, 36]. Furthermore, TLR9, which was
reported to be a target of IC31 R© [42] is expressed in different DC subsets in
mice and humans, and CpG sequences resulting in optimal immune response
are also species-specific [12,19,27].
Concerning the comparison between BALB/c and C57BL/6 mice in re-
sponse to IC31 R©, it has been reported that DCs isolated from the spleens of
naive C57BL/6 mice preferentially expressed TLR9 mRNA. [32]. Also, IL-12
production was much higher in C57BL/6 DC in response to phosphorothioate-
stabilized CpG ODN.
In addition to differences in the mucosal immune system, one must not
forget that man has 20-40% lymphocytes among white blood cells, whereas
mice have 50-70% [21].
Finally, the CTL epitopes identified here might be incorporated in a
multi-epitope vaccine, as demonstrated in a paper by Pinchuk et al. [38].
In this DNA-based vaccine, 7 CD8+ T cell epitopes and a CD4+ epitope are
combined, resulting in protective immunity against Cpn. Mucosal adminis-
tration of a similar construct, in combination with IC31 R©, might also prove
to be protective in mice.
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7 Materials and methods
7.1 Mice
Female BALB/c (H-2d) or C57BL/6 (H-2b) mice were obtained from Charles
River laboratories, Germany, or Harlan Winkelmann, Germany, at an age of
6-8 weeks. Experiments were initiated before mice reached an age of 12
weeks. Mice were kept in our animal facility under specific pathogen-free
conditions with free access to food and water. All animals experiments were
conducted according to Austrian Law.
7.2 Antigens
Chlamydia outer protein N (CopN, Low Calcium Response E [Chlamydophila
pneumoniae CWL029] Accession AAD18473) with an N-terminal 6xHis tag
was used throughout this study. CopN was overexpressed in E. coli BL21
Codon Plus under standard conditions. Lysis was performed via sonication
in 50 mM Tris pH 8.0, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100 (Fluka),
1 mM DTT (Serva) in the presence of protease inhibitors: 1 µg/ml pepstatin
A (Sigma), 1 µg/ml aprotinin (Sigma), 1 µg/ml leupeptin (Serva), 40 µM
bestatin (Sigma), 10 µM E-64 (Sigma), 1000 µM AEBSF(Serva). DNA was
digested using DNase 1 grade II (Roche).
Isolation was performed using gravity flow-columns with Ni-sepharose 6
fast flow (GE Healthcare). Washing occurred in 20 mM imidazole (Sigma),
50 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol and 0.5 mM DTT. Elution
was performed with 500 mM imidazole and 0.5 mM DTT in TNG buffer.
TNG buffer consisted of 50 mM Tris pH 8.0, 120 mM NaCl, 5 mM KCl
and 10% glycerol. The eluate was dialyzed against TNG buffer, followed by
sterile filtration.
Protein concentration was determined using the BCA Protein Assay
(Pierce). The amount of LPS-contamination was measured using the QCL-
1000 Endpoint Chromogenic Limulus Amoebocyte Lysate Assay (Lonza).
The peptide library which was used here consisted of 15-mers overlapping
by 10 amino acids, covering the entire sequence of CopN. Peptides were syn-
thesized in-house by solid phase synthesis on preloaded 2-chlorotrityl resins
(Pepchem) on a multiple peptide synthesizer (Syro, Multisyntech). After syn-
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thesis, peptides were cleaved from the resin and purified by RPHPLC. The
identity and purity was confirmed by mass spectroscopy using a MALDI-
TOF mass spectrometer Voyager-DE-STR (Applied Biosystems). Candidate
peptide epitopes were either synthesized in-house or purchsed from ProIm-
mune. All peptides were solubilized in DMSO (Sigma) to a concentration of
20 mg/mL. Peptides were stored at -20◦C until needed.
Irrelevant peptides 19 and 27 were also synthesized in-house. Peptide 19
has the sequence KIYNRNIVNRLLGD and encodes an H-2d-restricted cyto-
toxic T lymphocyte epitope [15]. Peptide 27 has the sequence CYHASVTDI
and encodes an H-2d-restricted cytotoxic T lymphocyte epitope [49].
Crystallized chicken Ovalbumin (Sigma) dissolved in PBS (Gibco) was
used as an irrelevant antigen for ex vivo re-stimulation of cells in ELISpot as-
says or activation-based assays using flow cytometry.
7.3 Adjuvants
KLKL5KLK (NH2-KLKLLLLLKLK-COOH) and ODN1a (phosphodiester
backbone ODN, oligo-(dIdC)13) were purchased from Bachem (KLK) and
Transgenomic (ODN1a). The individual components of IC31 R© were dis-
solved in 10 mM Tris, 135 mM NaCl (pH 7.5–8) at a stock concentration
of 2000 nmol KLK/80 nmol ODN1a. Before preparing the vaccine formula-
tion, this stock solution was mixed vigorously at RT. The final amount of
IC31 R© in the vaccine formulation is given in brackets throughout the text:
the first number designates the amount of KLK in nmol and the second the
amount of ODN1a in nmol.
Initially, also CFA and IFA (Difco) were used intraperitoneally. The
vaccine formulation consisted of 50% v/v of CFA for the first immunization
and IFA for subsequent immunitaions.
Cholera toxin or Cholera toxin b subunit (Sigma) and CpG1826 (Purimex)
were used at 10 µg/dose intranasally.
7.4 Vaccination of mice
Irrespective of route, 40 µg of CopN were administered. In the peptide-
immunization experiments, 50 nmol of peptide were administered. Intraperi-
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toneal vaccination of mice occurred in a volume of 200 µL per dose. Sub-
cutaneous vaccination of mice occurred in a volume of 100 µL per dose at
the left flank. Intranasal vaccination was performed under light anesthesia
of Isoflurane (Baxter) in a volume of 40 µL per dose, administered with a
pipettor. Vaccinations at the base of the tail were performed in 100 µL per
dose. Naïve mice or mice which received antigen or adjuvant alone served as
controls.
7.5 Infection of mice with Chlamydia pneumoniae
Mice received a hypothetical bacterial load of 1x106 Chlamydia pneumoniae
K6 IFUs/dose. This was performed intranasally, under light anesthesia.
7.6 Media
Unless stated otherwise, the medium used here consisted of RPMI 1640 + L-
glutamine (Gibco), 10% FCS (PAA), 20 mM HEPES (Gibco), 1 mM sodium
pyruvate (PAA), 0.1 mM non-essential amino acids (PAA), an additional 2 mM
L-glutamine (Gibco), 50 µM β-mercaptoathanol (Gibco), 100 units/mL penicillin
and 100 µg/mL streptomycin (PAA). This was defined as T cell medium (TCM).
For experiments with HEp-2 cells, no β-mercaptoathanol was added.
For subsequent experiments with Cpn, 100 µg/mL gentamycin (PAA) were
used instead of penicillin and streptomycin.
For Immunofluorescence microscopy experiments, the medium consisted of Is-
cove’s Modified Dulbecco’s Medium (Gibco), 10% FCS (PAA), 20 mM HEPES
(Gibco), 1 mM sodium pyruvate (PAA), 0.1 mM non-essential amino acids (PAA),
an additional 2 mM L-glutamine (Gibco), 0.26 mg/mL sodium-bicarbonate (PAA),
0.5 mg/mL glucose (Gibco) and 100 µg/mL gentamycin (PAA).
7.7 Cell preparation and purification
At different time-points after single and booster immunization or infection, mice
were sacrificed by cervical dislocation and spleens and/or lungs were collected. All
organs from animals in the same experimental groups were pooled and single cell
suspensions were prepared mechanically in TCM followed by the lysis of erythro-
cytes in a solution containing 155 mM NH4Cl, 10 mM KHCO3 and 10 µM EDTA
buffer pH 7.2-7.4. or in a commercially available erythrocyte lysis buffer (Sigma).
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Whenever possible, cells were stored on 4◦C. After washing, viable cell count was
determined by trypan blue exclusion staining.
If an isolation step was performed, cells were first washed in MACS-buffer
(0.5% BSA, 2 mM EDTA in PBS). For CD4 and CD8 depletion experiments, CD4
(L3T4) and CD8a (Ly-2) microbeads were used in combination with LD columns.
For isolation of lung T cells, the Pan T Cell Isolation Kit with pre-separation filters
and LS columns were used, according to the manufacturer’s instructions (MACS,
Miltenyi Biotec). Purity was determined by fluorescent staining of cells followed
by flow cytometry as outlined in section 7.9.
7.8 IFN-γ ELISpot assay
Sterile MS 96-well filtration plates for the IFN-γ ELISpot were purchased from Mil-
lipore (Cat. MAHAS4510). Wells were pre-wetted with PBS (Gibco) and coated
with anti-mouse IFN-γ antibody (BD Pharmingen) diluted in coating buffer to a
concentration of 3 µg/mL. Coating buffer was made of 8.4 g/L NaHCO3 in aqua
bidestillata (Mayrhofer Pharmaceuticals) pH 9.2-9.4. Coating was performed on
37◦C for at least one hour or on 4◦C in a humid chamber for at least one day.
Before the assay, plates were blocked with 1% BSA in PBS on 37◦C for one hour
or on RT for at least two hours.
After the blocking step, 2.5 − 10x105 cells in TCM were added per well. In
the case of APC-derived cells, a roughly equimolar amount of naïve spleen cells
was added. For the majority of experiments, these cells were irradiated with circa
20 Gy. Subsequently, stimuli were added. ConA (Sigma) was added as a positive
control. Usually, Ova, peptides 19 and 27 were added as irrelevant controls. TCM
was added as a negative control. Finally, RCAS (Becton Dickinson) was added to
a final concentration of 1%.
Incubation at 37◦C/5% CO2 usually lasted around 20 hours. For cultured
ELISpots, conditions were similar: cells were not placed in the ELISpot-plates,
but in standard round-bottom 96-well plates at a density of 1x106 cells/well. No
RCAS was added. After 48 hours of incubation, old medium was removed and cells
were transferred into ELISpot plates. Stimuli were added at half the concentration
as during the pre-culture. RCAS was added to a final concentration of 1%. Then
it was preceeded as in a standard IFN-γ ELISpot.
Afterwards, plates were washed with washing buffer, which consisted of 0.1%
Tween20 (Sigma) in PBS, for circa 15 min at RT. Biotin-labeled detection anti-
body (BD Pharmingen) was added to a final concentration of 1 µg/mL in PBS.
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Incubation on 37◦C lasted two hours or o/n, if incubated on 4◦C in a humid cham-
ber. After washing, Streptavidin-labeled horseraddish peroxidase (Roche) was
added and incubated on 37◦C for 30 min. After a last round of washing, substrate
was added, consisting of 0.8 mg/mL 3,3’-diaminobenzidine, 0.4 mg/mL NiCl2 and
0.015% H2O2 in 100 mM Tris. The reaction was performed on RT and was usually
terminated after circa 10 min by flushing the plates under cold tap water. The
dry plates were analyzed on a Bioreader 5000 (BioSys, Germany).
7.9 Flow cytometry
Antibodies were obtained from eBioscience and used at 1 µg/mL unless stated
otherwise. Antibodies used here were anti-CD4-FITC, anti-CD8a-PE, anti-CD8a-
FITC, anti-CD3e-APC, anti-CD107a-AF488 (circa 2 µg/mL) and anti-CD154-PE
as well as appropriate isotype controls. H2-Kd MHC class I pentamers against
B8.1 (KYASGNSEI) and E8.1 (DYFESRVPI) were APC-conjugated and pur-
chased from ProImmune. Pentamers were cross-titrated with anti-CD8 and used
at 8 µL per stain.
1 − 2x106 cells were stained in a total volume of 100 µL for 20-30 min at
4◦C. For pentamer experiments, incubation was exactly 10 minutes at RT. After
excessive washing cells were measured immediately on a FACSCalibur equipped
with CellQuest software (Becton Dickinson)
7.10 CD154 and CD107 assay
For the CD154 assay, 2x106 cells were plated in a 96-well U-bottom plate. Sub-
sequently, stimuli were added. SEB was used as a positive control. Finally, anti-
CD154, GolgiStop (Becton Dickinson, concentration as recommended) and RCAS
(final concentration: 1%) were added and cells were incubated at 37◦C/5% CO2
for 8 hours or overnight. Thereafter, the staining protocol outlined in the previous
section was performed.
For the CD107 assay, 1− 2x106 cells were plated in a 96-well U-bottom plate.
Subsequently, stimuli were added. ConA, PMA/Ionomycin and SEB were used as
a positive control. Finally, anti-CD107a, GolgiStop (Becton Dickinson, concentra-
tion as recommended) and RCAS (final concentration: 1%) were added and cells
were incubated at 37◦C/5% CO2 for 6 hours. Thereafter, the staining protocol
outlined in the previous section was performed.
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7.11 In vivo cytotoxicity assay
A single cell suspension from spleen cells from naïve mice was prepared and ad-
justed to 1x107 cells/mL in TCM. Aliquots were pulsed with stimuli at 10 µg/mL
or medium only at 37◦C/5% CO2 for 1 hour. Cells were gently washed with PBS
and adjusted to 2x107 cells/mL. Pulsed cells were incubated with 2.5 µM CFSE
and mock-pulsed cells were incubated with 0.25 µM CFSE for 3 minutes at 37◦C.
The labeling reaction was stopped by adding FCS to a final concentration of 10%.
After gently washing, cells were counted and adjusted to 2x108 cells/mL. Equal
parts of pulsed and mock-pulsed cells were mixed to yield 2x107 cells/100 µL. Each
mouse received 100 µL intranasally, under light anesthesia of isoflurane.
Lungs were harvested 18 hours later and cell suspensions were prepared for
each individual mouse. Flow cytometric analysis was performed immediately af-
terwards.
7.12 Serum preparation, antigen-specific ELISA
Terminal bleedings were collected with Vacutainer SST tubes (Becton Dickinson).
Serum was prepared as recommended in the manufacturer’s instructions and stored
at -37◦C until needed.
ELISA-plates (NUNC low binding Maxisorp) were coated with 70 µL of purified
CopN at 1 µg/mL in PBS at 4◦C over night. After washing the wells with PBS,
blocking was performed with 0.1% BSA in PBS at 37◦C for 30 min. Wells were
briefly washed with 0.05% Tween20. A dilution series of each serum sample was
performed in PBS-BSA-Tween (concentrations as before) and incubated at RT for
90 min. After washing with PBS-Tween, goat anti-mouse IgG (H+L) horseraddish-
peroxidase (Southern Biotech) detection antibody was added in PBS-BSA-Tween
and incubated at RT for 90 min. Wells were washed with PBS-Tween before ABTS
substrate solution (Sigma) was applied. After 10-20 min the colour intensity was
measured at 405 nm on a Tecan Sunrise microplate reader.
Using Prism 5 (GraphPad Software), a nonlinear regression was performed
across all data points and the titer that gave an optical density 50% between Top
and constrained Bottom was reported as the Best-Fit LOGECF50.
7.13 Immunofluorescence microscopy
HEp-2 cells were grown to confluence on coverslips placed inside 24-well plates.
After addition of Chlamydia pneumoniae K6, plates were centrifuged at 550xg on
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35◦C for 1 hour. New medium containing 0.5 µg of cycloheximide (Sigma) was
added. Incubation at 35◦C/5% CO2 lasted for circa 48 hours.
After washing with PBS (Gibco), -20◦C cold methanol (Merck) was carefully
added into the wells. After another washing step, a blocking step with 1% BSA in
PBS was performed for 1 hour. Primary antibodies were sera from immunized mice
(according to text) and rabbit anti Cpn0585 (B. Wizel). Incubation was peformed
in a dark humid chamber at RT for 1 hour. Coverslips were washed in PBS
and stained with secondary antibodies, which were AF488-conjugated goat anti-
mouse and AF594-conjugated goat anti-rabbit (Molecular Probes). Incubation was
performed as before, only for 30 minutes. Coverslips were washed and stained with
a 1 µg/mL solution of DAPI (Sigma) at RT for 10 minutes. After a final washing
step, coverslips were placed on a glass slide covered with Moviol. Analysis was
performed on an Axio Observer Z1 (Zeiss).
7.14 Linear B cell epitope screening
Circa 20 µg of peptide were spotted onto a PVDF Immobilon-P transfer membrane
(Millipore). The membrane was air-dried and placed into blocking buffer consisting
of 1% BSA in PBS for 30 minutes. After a brief washing step in PBS, serum from
immunized mice diluted in ab-buffer consisting of 0.1% BSA, 0.1% Tween20 in
PBS was added and incubated for 90 minutes at RT. Afterwards, the membrane
was washed in PBS. Goat anti-mouse IgG coupled to horseraddish peroxidase
(Southern Biotech) was used as secondary ab. diluted in ab-buffer. Incubation
was performed as before followed by a final washing step. The substrate solution
used here was the same as described in section 7.8. The reaction was stopped after
90 seconds and scanning was performed immediately.
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Oligo GEArray R©Mouse Inflammatory Cytokines
& Receptors Microarray
Functional Gene Grouping Chemokines and Cytokines: Ccl1, Ccl11, Ccl12,
Ccl17, Ccl19, Ccl2, Ccl20, Ccl21a, Ccl21b, Ccl22, Ccl24, Ccl25, Ccl3, Ccl4, Ccl5,
Ccl6, Ccl7, Ccl8, Ccl9, Cx3cl1, Cxcl1, Cxcl10, Cxcl11, Cxcl12, Cxcl13, Cxcl14,
Cxcl15, Cxcl2, Cxcl4, Cxcl5, Cxcl9, Ifna2, Ifng, Il10, Il11, Il12a, Il12b, Il13, Il15,
Il16, Il17, Il17b, Il17e, Il18, Il1a, Il1b, Il2, Il20, Il22, Il3, Il4, Il5, Il6, Il9, Lta, Ltb,
Mif, Scye1, Spp1, Tnf, Tnfsf5 (CD40 Ligand), Xcl1.
Chemokine Receptors and Cytokine Receptors: Blr1, Ccr1, Ccr2, Ccr3,
Ccr4, Ccr5, Ccr6, Ccr7, Ccr8, Ccr9, Cx3cr1, Cxcr3, Gpr2, Il10ra, Il10rb, Il12b,
Il12rb, Il13ra1, Il1r1, Il2rb, Il2rg, Il5ra, Il6ra, Il6st, Il9r, Xcr1.
Interleukins and Receptors: Il1r2, Il1rn, Il8ra, Il8rb, Il10, Il10rb, Il12a, Il12b,
Il13, Il18, Il18, Il1a, Il1b, Il1r1, Il1r2, Il2, Il20, Il3, Il4, Il5, Il6, Il9, Tollip.
TNF Ligands and Receptors: Tnfrsf1a, Tnfrsf1b, Lta, Ltb, Tnf (TNF-α),
Tnfsf5 (CD40 Ligand).
Other Factors Involved in the Inflammatory Response: C3, Fcer1g, Fcgr1,
Igh-4, Itgam, Itgb2, Nos2, Prkca, Rac1, Tgfb1, Tlr1, Tlr2, Tlr3, Tlr4, Tlr5, Tlr6,
Tlr7, Tlr8, Tlr9.
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